Cited 4 times in
Association of MGMT Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type IDH Glioblastoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김세훈 | - |
dc.contributor.author | 유지환 | - |
dc.contributor.author | 장종희 | - |
dc.date.accessioned | 2022-03-11T05:55:02Z | - |
dc.date.available | 2022-03-11T05:55:02Z | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187862 | - |
dc.description.abstract | Background: The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter plays a key role in response to temozolomide chemotherapy and disease prognosis in patients with wild-type isocitrate dehydrogenase (IDH) glioblastoma (GBM). Patients and methods: The MGMT promoter methylation status and its association with clinicopathological parameters were retrospectively analysed in a cohort of 316 patients with GBM with wild-type IDH. Results: MGMT methylation was significantly associated with ATRX chromatin remodeler (ATRX) loss and completion of the standard Stupp protocol. The median durations of overall and progression-free survival for the unmethylated, low-methylated (10-39%), and hypermethylated (≥40%) groups were 15, 23, and 30 months and 11, 18, and 21 months, respectively. However, the improvement in the survival of the hypermethylated group was not statistically significant. Conclusion: We suggest a possible association between MGMT methylation status and ATRX mutations in GBM with wild-type IDH. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | International Institute of Anticancer Research | - |
dc.relation.isPartOf | ANTICANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Association of MGMT Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type IDH Glioblastoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학교실) | - |
dc.contributor.googleauthor | Moonsik Kim | - |
dc.contributor.googleauthor | Jihwan Yoo | - |
dc.contributor.googleauthor | Jong Hee Chang | - |
dc.contributor.googleauthor | Se Hoon Kim | - |
dc.identifier.doi | 10.21873/anticanres.15490 | - |
dc.contributor.localId | A00610 | - |
dc.contributor.localId | A05158 | - |
dc.contributor.localId | A03470 | - |
dc.relation.journalcode | J00188 | - |
dc.identifier.eissn | 1791-7530 | - |
dc.identifier.pmid | 34969742 | - |
dc.identifier.url | https://ar.iiarjournals.org/content/42/1/335.long | - |
dc.subject.keyword | ATRX loss | - |
dc.subject.keyword | MGMT | - |
dc.subject.keyword | glioblastoma | - |
dc.subject.keyword | hypermethylation | - |
dc.subject.keyword | low methylation | - |
dc.subject.keyword | methylation status | - |
dc.subject.keyword | temozolomide chemotherapy | - |
dc.subject.keyword | wild-type IDH | - |
dc.contributor.alternativeName | Kim, Se Hoon | - |
dc.contributor.affiliatedAuthor | 김세훈 | - |
dc.contributor.affiliatedAuthor | 유지환 | - |
dc.contributor.affiliatedAuthor | 장종희 | - |
dc.citation.volume | 42 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 335 | - |
dc.citation.endPage | 341 | - |
dc.identifier.bibliographicCitation | ANTICANCER RESEARCH, Vol.42(1) : 335-341, 2022-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.